The tender offer was originally scheduled to expire on December 23, 2008. All other terms and conditions of the tender offer remain unchanged. As previously disclosed, the conditions
EXACT’s total revenues increased due to strategic relationship with Genzyme Corp. Exact in January entered into an intellectual property transaction with Genzyme that generated $17.2 million in cash.
Under the terms of the agreement, GlaxoSmithKline (GSK) is expected to pay Ligand $5m as an upfront license fee, up to $158m in development and commercial milestones and a 16%
With this transaction, Radi Medical Systems will become part of the St Jude Medical cardiovascular division. The transaction is expected to be neutral to St Jude Medical’s consolidated
Progen will propose to shareholders a A$20 million share buyback option, to be completed prior to the merger. The combined entity will have over A$60 million cash at
The protocols for the two studies 102 and 030 were reviewed and prospectively approved by the FDA under its special protocol assessment (SPA) procedure. Both studies achieved their
In this study, the efficacy of multiple doses of 600mg of MEM 1414 on the allergen-induced asthmatic response in steroid free subjects with mild allergic asthma will be
In conjunction with this transaction, EMD Serono Canada, an affiliate of Merck KGaA, has assumed control of Oncothyreon’s facility in Edmonton, Canada, which is primarily utilized for the
The company is planning to treat amyotrophic lateral sclerosis (ALS) patients through spinal injections of its stem cells via its patented human neural stem cell technology. Neuralstem expects
ACT III is a randomized open-label, two-arm, Phase IIb/III trial comparing CDX-110 combined with temozolomide to temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM). Only the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.